167 related articles for article (PubMed ID: 17032887)
1. Modeling the impact of adjuvant therapy and screening mammography on U.S. breast cancer mortality between 1975 and 2000: introduction to the problem.
Feuer EJ
J Natl Cancer Inst Monogr; 2006; (36):2-6. PubMed ID: 17032887
[No Abstract] [Full Text] [Related]
2. Additional common inputs for analyzing impact of adjuvant therapy and mammography on U.S. mortality.
Cronin KA; Mariotto AB; Clarke LD; Feuer EJ
J Natl Cancer Inst Monogr; 2006; (36):26-9. PubMed ID: 17032891
[TBL] [Abstract][Full Text] [Related]
3. Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000: comparison of mortality results from the cisnet breast cancer base case analysis.
Cronin KA; Feuer EJ; Clarke LD; Plevritis SK
J Natl Cancer Inst Monogr; 2006; (36):112-21. PubMed ID: 17032901
[TBL] [Abstract][Full Text] [Related]
4. Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach.
Berry DA; Inoue L; Shen Y; Venier J; Cohen D; Bondy M; Theriault R; Munsell MF
J Natl Cancer Inst Monogr; 2006; (36):30-6. PubMed ID: 17032892
[TBL] [Abstract][Full Text] [Related]
5. The SPECTRUM population model of the impact of screening and treatment on U.S. breast cancer trends from 1975 to 2000: principles and practice of the model methods.
Mandelblatt J; Schechter CB; Lawrence W; Yi B; Cullen J
J Natl Cancer Inst Monogr; 2006; (36):47-55. PubMed ID: 17032894
[TBL] [Abstract][Full Text] [Related]
6. The MISCAN-Fadia continuous tumor growth model for breast cancer.
Tan SY; van Oortmarssen GJ; de Koning HJ; Boer R; Habbema JD
J Natl Cancer Inst Monogr; 2006; (36):56-65. PubMed ID: 17032895
[TBL] [Abstract][Full Text] [Related]
7. A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000.
Plevritis SK; Sigal BM; Salzman P; Rosenberg J; Glynn P
J Natl Cancer Inst Monogr; 2006; (36):86-95. PubMed ID: 17032898
[TBL] [Abstract][Full Text] [Related]
8. Screening and breast cancer.
Gøtzsche PC
N Engl J Med; 2006 Feb; 354(7):767-9; author reply 767-9. PubMed ID: 16482679
[No Abstract] [Full Text] [Related]
9. Effect of screening and adjuvant therapy on mortality from breast cancer.
Berry DA; Cronin KA; Plevritis SK; Fryback DG; Clarke L; Zelen M; Mandelblatt JS; Yakovlev AY; Habbema JD; Feuer EJ;
N Engl J Med; 2005 Oct; 353(17):1784-92. PubMed ID: 16251534
[TBL] [Abstract][Full Text] [Related]
10. Age-related accuracy of screening mammography: how should it be measured?
Feig SA
Radiology; 2000 Mar; 214(3):633-40. PubMed ID: 10715022
[No Abstract] [Full Text] [Related]
11. The Wisconsin Breast Cancer Epidemiology Simulation Model.
Fryback DG; Stout NK; Rosenberg MA; Trentham-Dietz A; Kuruchittham V; Remington PL
J Natl Cancer Inst Monogr; 2006; (36):37-47. PubMed ID: 17032893
[TBL] [Abstract][Full Text] [Related]
12. Modeling cancer natural history, epidemiology, and control: reflections on the CISNET breast group experience.
Habbema JD; Schechter CB; Cronin KA; Clarke LD; Feuer EJ
J Natl Cancer Inst Monogr; 2006; (36):122-6. PubMed ID: 17032902
[No Abstract] [Full Text] [Related]
13. Screening and breast cancer.
Smith DW
N Engl J Med; 2006 Feb; 354(7):767-9; author reply 767-9. PubMed ID: 16482677
[No Abstract] [Full Text] [Related]
14. Screening and breast cancer.
Baker SG
N Engl J Med; 2006 Feb; 354(7):767-9; author reply 767-9. PubMed ID: 16481650
[No Abstract] [Full Text] [Related]
15. Mammography in younger women: the dilemma of diminishing returns.
Calonge N
J Natl Cancer Inst; 2010 May; 102(10):668-9. PubMed ID: 20439837
[No Abstract] [Full Text] [Related]
16. The effects of population-based mammography screening starting between age 40 and 50 in the presence of adjuvant systemic therapy.
de Gelder R; Heijnsdijk EA; Fracheboud J; Draisma G; de Koning HJ
Int J Cancer; 2015 Jul; 137(1):165-72. PubMed ID: 25430053
[TBL] [Abstract][Full Text] [Related]
17. [Significance of roentgen mammography for breast carcinoma screening].
Schulz-Wendtland R; Krämer S; Döinghaus K; Säbel M; Lang N; Bautz W
Rontgenpraxis; 1997 May; 50(5):103-9. PubMed ID: 9297252
[No Abstract] [Full Text] [Related]
18. Modeling the dissemination of mammography in the United States.
Cronin KA; Yu B; Krapcho M; Miglioretti DL; Fay MP; Izmirlian G; Ballard-Barbash R; Geller BM; Feuer EJ
Cancer Causes Control; 2005 Aug; 16(6):701-12. PubMed ID: 16049809
[TBL] [Abstract][Full Text] [Related]
19. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
20. Optimal screening schedules for prevention of metastatic cancer.
Hanin L; Pavlova L
Stat Med; 2013 Jan; 32(2):206-19. PubMed ID: 22807074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
